Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-01-18Clinical Trial Update: Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine [Phase 3]
Phase 3 trial comparing SAR342434 to Humalog as rapid-acting insulin in adults with type 2 diabetes also using insulin glargine has complete…
-
CLINICAL_TRIALS trial_result · 2018-01-18Clinical Trial Update: Sitagliptin in the Elderly [Phase 2]
Phase 2 trial update for sitagliptin in elderly patients with type 2 diabetes.
-
CLINICAL_TRIALS trial_result · 2018-01-18Clinical Trial Update: Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes [Phase 2]
Phase 2 trial assessing safety and efficacy of biphasic remogliflozin etabonate for type 2 diabetes mellitus has completed.
-
CLINICAL_TRIALS trial_result · 2018-01-18Clinical Trial Update: Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 Diabetes [Phase 2]
Phase 2 trial comparing GlucoNorm with glyburide for post-prandial hyperglycemia in elderly with type 2 diabetes; the study status is comple…
-
CLINICAL_TRIALS trial_result · 2018-01-17Clinical Trial Update: Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes [Phase 3]
Phase 3 trial comparing FIAsp-based basal-bolus regimen to basal insulin therapy, both with metformin, in adults with type 2 diabetes; study…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-01-17Clinical Trial Update: A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics [Phase 2]
Phase 2 study in type 2 diabetes assessing safety, tolerability, PK/PD of single and multiple oral doses of GSK1292263; study completed with…
-
CLINICAL_TRIALS trial_result · 2018-01-12Clinical Trial Update: Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes. [Phase 3]
Phase 3 trial assessing the effects of linagliptin on renal endothelium function in patients with type 2 diabetes has completed.
-
CLINICAL_TRIALS trial_result · 2018-01-12Clinical Trial Update: A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus [Phase 2]
Phase 2 trial update for LGD-6972 in type 2 diabetes mellitus has completed recruitment and status is completed.
-
CLINICAL_TRIALS trial_result · 2018-01-09Clinical Trial Update: The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes [Phase 4]
Phase 4 trial comparing Exenatide to Lantus insulin assessing vascular function in type 2 diabetes; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2018-01-08Clinical Trial Update: Effect of Morning Versus Evening Perindopril on Blood Pressure Control in People With Type 2 Diabetes [Phase 4]
A Phase 4 trial comparing morning versus evening dosing of perindopril for blood pressure control in adults with type 2 diabetes and hyperte…
-
CLINICAL_TRIALS trial_result · 2018-01-03Clinical Trial Update: Heart Rate Variability in Response to Metformin Challenge [Phase 2]
Phase 2 trial update on heart rate variability in response to a metformin challenge; completed with posted results.
-
FDA approval · 2018-01-02FDA Approved: INVOKAMET XR — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for INVOKAMET XR, a fixed-dose extended-release combination of canagliflozin and metformin hydro…
-
CLINICAL_TRIALS trial_result · 2017-12-28Clinical Trial Update: BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus [Phase 2]
Phase 2 trial update of BI 1356 BS in Japanese patients with Type 2 diabetes mellitus has completed.
-
FDA approval · 2017-12-27FDA Approved: GLIMEPIRIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for glimepiride submitted by Rising Pharma Holdings, Inc., expanding the regulatory status of th…
-
CLINICAL_TRIALS trial_result · 2017-12-26Clinical Trial Update: Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes [Phase 4]
Phase 4 clinical trial comparing short-term effects of liraglutide versus vildagliptine on insulin secretion and insulin sensitivity in type…
-
CLINICAL_TRIALS trial_result · 2017-12-26Clinical Trial Update: Role of Pancreatic Triglyceride Content in Beta-cell Function
A completed clinical trial investigating how pancreatic triglyceride content affects beta-cell function in obesity and type 2 diabetes.
-
CLINICAL_TRIALS trial_result · 2017-12-22Clinical Trial Update: OXEMET™ 1000 mg Coated Tablets (Metformin Hydrochloride) Bioequivalence Study. OXEMET (TM) is a Trademark of the GlaxoSmithKline Group of Companies. GLAFORNIL(TM) is a Trademark of Merck. [Phase 4]
Phase 4 bioequivalence study of OXEMET 1000 mg coated tablets (metformin hydrochloride) with GLAFORNIL; completed with results posted in 201…
-
CLINICAL_TRIALS trial_result · 2017-12-22Clinical Trial Update: Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes [Phase 4]
Phase 4 clinical trial investigating genetic influences on response to beta-blocker medications in individuals with type 2 diabetes.
-
FDA approval · 2017-12-21FDA Approved: ALOGLIPTIN AND PIOGLITAZONE — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
The FDA approved a supplemental application for the alogliptin and pioglitazone fixed-dose combination from Padagis Israel Pharmaceuticals L…
-
FDA approval · 2017-12-21FDA Approved: PIOGLITAZONE AND GLIMEPIRIDE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application from Prasco Laboratories for a Pioglitazone and Glimepiride product. This adds a fixed-dose combinat…
-
FDA label_change · 2017-12-21FDA Approved: ACTOPLUS MET — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for ACTOPLUS MET (pioglitazone and metformin hydrochloride) filed by Takeda to update the drug's…
-
CLINICAL_TRIALS trial_result · 2017-12-20Clinical Trial Update: A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes [Phase 1, Phase 2]
A clinical trial update for LY3053102 in type 2 diabetes was terminated; results were posted in 2017.
-
FDA approval · 2017-12-19FDA Approved: STEGLATRO — Original Application (Merck Sharp & Dohme LLC)
FDA approved STEGLATRO (ertugliflozin) in its original application for adults with type 2 diabetes mellitus to improve glycemic control, inc…
-
FDA approval · 2017-12-19FDA Approved: STEGLUJAN — Original Application (Merck Sharp & Dohme LLC)
FDA approved the original application for Steglujan, a fixed-dose combination of ertugliflozin and sitagliptin, for improving glycemic contr…
-
FDA approval · 2017-12-19FDA Approved: SEGLUROMET — Original Application (Merck Sharp & Dohme LLC)
FDA approved Segluromet (ertugliflozin and metformin hydrochloride) under an original application by Merck Sharp & Dohme LLC for the treatme…